Bayer agrees to help make CureVac’s COVID-19 vaccine
BERLIN (Reuters) – German pharmaceutical giant Bayer said on Monday it will help CureVac produce its experimental COVID-19 vaccine, the latest drugmaker to offer up manufacturing capacity as supplies fall behind demand.
Bayer said it expects to produce 161 million doses of CureVac’s experimental vaccine, which is currently in late-stage testing, in 2022, its head of pharma Stefan Oelrich told a news conference. (Reporting by Caroline Copley; editing by Thomas Seythal)
You Might Also Like
-
Bulawayo Bureau The Government has said it is no longer mandatory to wear face masks indoors, but highly recommended, a pronouncement that has seen education authorities saying pupils must continue to wear them. Last Friday, the World Health Organisation (WHO) declared that Covid-19 was no longer a public health emergency of international concern. However, WHO […]
Agriculture Journal
Comments